Controversies on individualized prostate cancer care: gaps in current practice

Joniau, Steven; Pfister, D.; Taille, Alexandre de la; Gaboardi, Franco; Thompson, Alan; Ribal, María J.

doi:10.1177/1756287213490053

Cited by 6 publications

(5 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the biological heterogeneity of PCa and rapidly expanding treatment options, individualized risk-adapted therapy incorporating patient- and tumor-specific characteristics is required to optimize outcome and avoid over-treatment with unnecessary adverse effects [ 3 , 4 ]. Since not only radical prostatectomy (RPE) or radiation, but also active surveillance possibly postponing definite therapy, currently represent state-of-the-art care for patients with a localized PCa and a long life expectancy [ 5 ], identifying cancer types with high progression risk is indispensable in determining a treatment course.…”

Section: Introductionmentioning

confidence: 99%

sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients

Tsaur

Thurn

Juengel

et al. 2015

J Exp Clin Cancer Res

View full text Add to dashboard Cite

BackgroundMeasurement of prostate-specific antigen (PSA) advanced the diagnostic and prognostic potential for prostate cancer (PCa). However, due to PSA’s lack of specificity, novel biomarkers are needed to improve risk assessment and ensure optimal personalized therapy. A set of protein molecules as potential biomarkers was therefore evaluated in serum of PCa patients.MethodsSerum samples from patients undergoing radical prostatectomy (RPE) for biopsy-proven PCa without neoadjuvant treatment were compared to serum samples from healthy subjects. Preliminary screening of 119 proteins in 10 PCa patients and 10 controls was carried out by the Proteome Profiler Antibody Array. Those markers showing distinct differences between patients and controls were then further evaluated by ELISA in the serum of 165 PCa patients and 19 controls. Uni- and multivariate as well as correlation analysis were performed to test the capability of these molecules to detect disease and predict pathological outcome.ResultsScreening showed that soluble (s)E-cadherin, E-selectin, MMP2, MMP9, TIMP1, TIMP2, Galectin and Clusterin warranted further evaluation. sE-Cadherin, TIMP1, Galectin and Clusterin were significantly over- and MMP9 under-expressed in PCa compared to controls. The concentration of sE-cadherin, MMP2 and Clusterin correlated negatively and that of MMP9 and TIMP1 positively with the Gleason Sum at prostatectomy. Only sE-cadherin significantly correlated with the highest Gleason pattern. Compared to serum PSA, sE-cadherin provided an independent and better matching predictive ability for discriminating PCas with an upgrade at RPE and aggressive tumors with a Gleason Sum ≥7.ConclusionssE-cadherin performed most favorably from a large panel of serum proteins in terms of diagnostic and predictive potential in curatively treatable PCa. sE-cadherin merits further investigation as a biomarker for PCa.

show abstract

Section: Introductionmentioning

confidence: 99%

sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients

Tsaur

Thurn

Juengel

et al. 2015

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…In this study, the patients’ age of prostate cancer diagnosis was older and in more advance stages compared to prostate cancers in North America which might reflect the lack of population awareness and cancer promotion as pivotal factors causing delayed on diagnosis [ 9 ]. In addition, advanced stages of prostate cancer at diagnosis (ISUP score more than 3) and higher PSA levels at diagnosis were dominant in this study.…”

Section: Discussionmentioning

confidence: 99%

Down-regulation of RB1 and TP53 as potential predicting biomarkers for castration-resistant prostate cancer (CRPC): Indonesian retrospective cohort study

Soerohardjo

Widodo

Heriyanto

et al. 2020

Annals of Medicine and Surgery

View full text Add to dashboard Cite

Introduction Androgen deprivation therapy (ADT) has remained the first line strategy for treatment of advanced prostate cancers. Despite the profound efficacy of ADT in preventing clinical remission, 30–50% of advanced prostate cancer will develop resistance to hormonal deprivation therapy. This study aimed to evaluate the potential role of RB1 and TP53 expressions as biomarkers for predicting time to castration-resistant prostate cancer (CRPC). Methods The clinical and pathological data of patients with prostate cancer were collected retrospectively from Dr. Sardjito General Hospital, Yogyakarta. Between 2015 and 2019, a total of 36 patients who received castration were included. Expressions of mRNA of RB1 and TP53 from primary tumors were quantified using quantitative Real Time Polymerase Chain Reaction (qRT-PCR). Results The expressions of mRNA of RB1 and TP53 increased in prostate cancer tissues compared to hyperplastic prostates and significantly downregulated in metastatic prostate cancers ( p < 0.001). Lower mRNA TP53 expression correlated with shorter time to CRPC among patients treated with ADT ( p = 0.006). In addition, stratified analysis showed that lower mRNA RB1 expression was significantly associated with shorter CRPC both in metastatic ( p = 0.017) and non-metastatic ( p = 0.001) prostate cancer patients. Conclusions Low expression of mRNA of RB1 and TP5 3 has been shown to be a potential marker of shorter time to develop CRPC in patients with advanced stages of prostate cancer treated with ADT. Meanwhile, ISUP score >4 were not shown predictive value on time to CRPC.

show abstract

“…Given the prevalence of CaP, 14 attention to the quality of CaP care has become an important health care issue not only for authorities and policy makers, but also for health service providers and patients. There is broad consensus on the need for regular assessment and monitoring of clinical performance, both for professional development and for quality improvement 15 . National data on CaP treatment are limited, and PCOR‐Vic was set up as a quality improvement project in 2009 to address this need 5 …”

Section: Discussionmentioning

confidence: 99%

“…There is broad consensus on the need for regular assessment and monitoring of clinical performance, both for professional development and for quality improvement. 15 National data on CaP treatment are limited, and PCOR-Vic was set up as a quality improvement project in 2009 to address this need. 5 Our analysis found a downward trend over a 5-year period in the percentage of men with low risk disease who underwent active treatment, an upward trend in the percentage of those with high risk and locally advanced disease who received active treatment within 12 months of diagnosis, and a decline in PSM in men with pathological T2 disease after radical prostatectomy.…”

Section: Discussionmentioning

confidence: 99%

Quality of care achievements of the Prostate Cancer Outcomes Registry–Victoria

Sampurno

Earnest

Kumari

et al. 2016

Medical Journal of Australia

View full text Add to dashboard Cite

Objective: To analyse the performance of the quality of prostate cancer (CaP) care over a 5‐year period with reference to three quality indicators (QIs) reported by the Prostate Cancer Outcomes Registry–Victoria (PCOR‐Vic): QI‐1: Alignment with the modified Prostate Cancer Research International Active Surveillance (PRIAS) protocol guideline; QI‐2: Timeliness of CaP care for men with high risk and locally advanced disease; QI‐3: Positive surgical margins (PSMs) for organ‐confined pathological T2 disease. Design, setting and participants: Between 1 January 2009 and 31 December 2013, 4708 men diagnosed with CaP who met the QI‐1, QI‐2 or QI‐3 inclusion criteria were recruited from Victorian hospitals. Outcome measures and statistical analysis: Trend analysis was conducted to monitor performance according to QI‐1, QI‐2 and QI‐3. We used the autoregressive integrated moving average (ARIMA) model to account for any inherent autocorrelation in the data when analysing the monthly incidence of each indicator. Differences in the annual figures for the indicators across years were also analysed by aggregating data by year and applying the ARIMA model. Results and limitations: There was a downward trend over the 5 years in the percentage of men with low risk disease who underwent active treatment (45% to 34%; P = 0.024), an upward trend in the percentage of those with high risk and locally advanced disease who received active treatment within 12 months of diagnosis (88% to 93%; P = 0.181), and a decline in PSM rate in men with pathological T2 disease after radical prostatectomy (21% to 12%; P = 0.036). Limitations of the study include the fact that the improvement in the QIs was detected using PCOR‐Vic as a single population, but there may be institutional variations in quality improvement. Conclusions: Over 2009–2013, the performance of the Victorian health system improved according to the three processes of care indicators reported by the PCOR‐Vic.

show abstract

Controversies on individualized prostate cancer care: gaps in current practice

Cited by 6 publications

References 82 publications

sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients

sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients

Down-regulation of RB1 and TP53 as potential predicting biomarkers for castration-resistant prostate cancer (CRPC): Indonesian retrospective cohort study

Quality of care achievements of the Prostate Cancer Outcomes Registry–Victoria

Contact Info

Product

Resources

About